The research, led by Wen Sun of the Centre for Translational Medicine at Shenzhen Bao’an Chinese Medicine Hospital, together with colleagues at institutions including Harbin Medical University, Southern Medical University and the Puensum Genetech Institute, took an unusually resourceful approach. Rather than recruiting a new cohort, the team reanalyzed publicly available fecal metagenomic data covering 307 samples. The dataset included healthy controls, patients with gout who had not yet received treatment, longitudinal samples collected after treatment began, and an independent validation cohort. By mining existing sequencing data for fungal reads, the researchers could ask a question that the original studies were not designed to answer: what happens to the fungal kingdom when the body is in a state of hyperuricemia and urate crystal-driven inflammation?

Technically, this was no trivial exercise. Most human gut metagenomic pipelines are calibrated for bacteria, and fungal sequences are easily lost in the noise or misclassified. The team therefore built their fungal profiles against a customized fungal reference database, drawing on resources such as the Unified Human Gastrointestinal Genome catalogue and curated collections of cultivated gut fungi, alongside reference genomes from the National Center for Biotechnology Information. To identify which fungal taxa genuinely distinguished gout patients from healthy individuals, they used MaAsLin2, short for Microbiome Multivariable Association with Linear Models 2, a statistical framework that models each taxon’s abundance while adjusting for available covariates such as age, body mass index and other confounders. This covariate adjustment matters enormously in microbiome studies, where diet, medication and demographics can masquerade as disease signals.

The first headline finding concerns the shape of the disturbance. Gout patients did not show a wholesale collapse or explosion of fungal diversity. Alpha diversity, the within-sample measure of how many fungal species are present and how evenly they are distributed, was largely unchanged. What shifted instead was the structure of the community as a whole, the beta diversity, indicating that specific fungal taxa had risen or fallen rather than the ecosystem being globally disrupted. In other words, gout appears to be associated with a taxon-specific fungal dysbiosis, a surgical rather than scorched-earth alteration of the mycobiome. This nuance is important, because global diversity loss is often interpreted as a hallmark of disease-associated dysbiosis, and its absence here suggests a more targeted perturbation.

Drilling down to individual organisms, the analysis identified four differential fungal genera and six candidate fungal species that separated gout patients from controls. Three species were enriched in healthy controls: Cutaneotrichosporon c141, Cyberlindnera jadinii c124 and Phialophora verrucosa c161. Three others were enriched in gout patients: Aspergillus terreus c60, Pichia fermentans c90 and Torulaspora delbrueckii c85. The naming convention, with strain-level codes appended to species names, reflects the precision of the customized database, which could resolve fungi to the level of individual strains rather than stopping at genus or species. That resolution is critical, because closely related fungal strains can carry very different metabolic repertoires, and lumping them together would wash out exactly the signals the study was hunting for.

One of the most intriguing parts of the study is its longitudinal dimension. Because the dataset included samples taken from gout patients before and after treatment, the researchers could ask whether the fungal signatures respond to therapy. The answer was a qualified yes: treatment produced partial and heterogeneous remodeling of the fungal landscape. Some of the gout-associated shifts eased, but the recovery was neither uniform across patients nor complete. This heterogeneity echoes what is seen in bacterial microbiome studies, where individual patients respond to interventions in idiosyncratic ways, and it suggests that fungal communities are not simply passive mirrors of disease status but dynamic ecosystems with their own trajectories.

The team then probed how the fungal changes relate to the rest of the microbial and clinical picture. Using Procrustes analysis, a geometric method for testing whether two datasets preserve the same underlying structure, and cross-kingdom network analysis linking microbes to clinical variables, they found that fungal alterations were associated with bacterial community structure and with clinical indicators related to renal function and inflammation. This matters because gout is fundamentally a disease of urate handling, in which the kidneys play a central role, and because chronic inflammation driven by monosodium urate crystal deposition in joints is what turns elevated uric acid into agonizing arthritis. The correlation between fungal composition and these clinical markers hints that fungi could be woven into the disease biology rather than merely co-occurring with it, though correlation alone cannot establish direction or causation.

Going a step deeper into fungal biology, the researchers performed genome mining on the candidate biomarker species, cataloguing their predicted biosynthetic gene clusters, the genomic modules that encode the enzymes for producing secondary metabolites such as polyketides, nonribosomal peptides and ribosomally synthesized post-translationally modified peptides. These clusters are the chemical factories of fungi, responsible for compounds that can modulate host immunity or microbial competition. The analysis revealed distinct predicted biosynthetic gene cluster profiles among the candidate fungal biomarkers, meaning that the gout-enriched and control-enriched fungi differ not just in their abundance but in their potential chemical capabilities. Whether those capabilities are actually deployed in the gut, and whether any of the resulting metabolites influence urate metabolism or inflammatory pathways, remains an open question that the study rightly flags for future functional work.

The study is also refreshingly honest about the limits of its predictive power. Random forest models, a machine learning approach that combines many decision trees to classify samples, showed that fungal features alone had limited ability to distinguish gout patients from controls. However, when fungal signatures were integrated with bacterial signatures, they provided complementary information, improving the overall picture beyond what bacteria alone could offer. This is a realistic and valuable conclusion: the mycobiome is unlikely to serve as a standalone diagnostic for gout, but ignoring it means discarding a layer of information that the bacterial microbiome does not fully capture. In the emerging framework of multi-kingdom microbiome science, fungi may be a small but non-redundant piece of the puzzle.

The authors are careful to frame their conclusions as exploratory. The work relies on reanalyzed public data, which brings unavoidable heterogeneity in cohort characteristics, sequencing protocols and metadata quality, and the findings require validation in larger, purpose-built controlled cohorts before any clinical implications can be drawn. Still, the study opens a genuinely underexplored frontier. Gout affects hundreds of millions of people worldwide, and its rising prevalence tracks with diets rich in purines, alcohol and fructose, factors that also shape the gut environment in which fungi live. If future work confirms that specific fungi contribute to hyperuricemia or to the inflammatory cascade of gout flares, the mycobiome could become a target for probiotic, dietary or antifungal strategies alongside conventional urate-lowering therapy. For now, the message is simpler but striking: when scientists finally looked at the fungal half of the gut microbiome in gout, it was not silent after all.

Subject of Research: Gut mycobiome alterations in patients with gout

Article Title: Metagenomic profiling reveals distinct gut mycobiome signatures in patients with gout

Article References: Sun, W., Yang, M., Sang, X., Guo, S., Zhang, Y., Wu, X., Chen, H., Xing, G., Li, M., Zhang, Y., Fan, S., Lu, T., Yan, Q., Li, S., Zhou, P., Yang, W., Chen, C., & Huang, L. (2026). Metagenomic profiling reveals distinct gut mycobiome signatures in patients with gout. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08840-5

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08840-5

Keywords: gout, gut mycobiome, metagenomics, fungal dysbiosis, microbiome, hyperuricemia, biosynthetic gene clusters, random forest, cross-kingdom interactions, Journal of Translational Medicine, inflammation, renal function